RT Journal Article
T1 Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
A1 Nishio, Makoto
A1 Barlesi, Fabrice
A1 West, Howard
A1 Ball, Simon
A1 Bordoni, Rodolfo
A1 Cobo, Manuel
A1 Longeras, Pascale Dubray
A1 Goldschmidt, Jerome
A1 Novello, Silvia
A1 Orlandi, Francisco
A1 Sanborn, Rachel E
A1 Szalai, Zsuzsanna
A1 Ursol, Grigoriy
A1 Mendus, Diana
A1 Wang, Lijia
A1 Wen, Xiaohui
A1 McCleland, Mark
A1 Hoang, Tien
A1 Phan, See
A1 Socinski, Mark A
K1 Atezolizumab
K1 Lung cancer
K1 Nonsquamous
K1 Non–small cell
AB We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with nonsquamous NSCLC. Chemotherapy-naive patients with stage IV nonsquamous NSCLC without sensitizing EGFR or ALK genetic alterations were randomized in a one-to-one ratio to receive four or six cycles of carboplatin or cisplatin plus pemetrexed (PP) or APP every 3 weeks, followed by maintenance therapy with atezolizumab plus pemetrexed or pemetrexed alone. Co-primary end points were overall survival (OS) and investigator-assessed progression-free survival (PFS). The intention-to-treat population included 578 patients (APP, n = 292; PP, n = 286). At the primary PFS analysis (May 22, 2018; median follow-up, 14.8 mo), APP exhibited significant PFS improvement versus PP (median = 7.6 versus 5.2 mo, stratified hazard ratio [HR] = 0.60, 95% confidence interval [CI]: 0.49-0.72, p  IMpower132 met its co-primary PFS end point but not its co-primary OS end point, with numerical improvement for OS in the APP arm. APP had a manageable safety profile, with no new or unexpected safety signals identified.
PB Elsevier
YR 2020
FD 2020-12-14
LK http://hdl.handle.net/10668/16813
UL http://hdl.handle.net/10668/16813
LA en
NO Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, et al. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. J Thorac Oncol. 2021 Apr;16(4):653-664
DS RISalud
RD Apr 10, 2025